On April 2, 2026, BVF Partners L.P. executed a significant sale of 3,750,000 shares of MoonLake Immunotherapeutics (MLTX), raising approximately $62.96 million at a weighted average price of $16.79 per share. This transaction marks BVF’s largest direct sale of MLTX stock to date, surpassing its previous sale of 2,000,000 shares, although the overall sample size remains limited.
This sale reduces BVF’s direct holdings in MoonLake to 15.9 million shares, still representing a substantial investment in the company, which is focused on developing its investigational therapy sonelokimab for inflammatory diseases. Despite the sale, BVF’s stake remains a modest 8.76% of its total assets under management, indicating a strategic trimming of exposure rather than a complete divestment. MoonLake’s recent positive clinical trial results have contributed to a rebound in its stock price, suggesting ongoing investor interest.
For market professionals, this transaction signals a potential rebalancing in BVF’s portfolio while highlighting MoonLake’s continued growth prospects in the biotechnology sector. The volatility inherent in biotech investments, coupled with BVF’s retained stake, suggests that MoonLake may still be viewed as a long-term play, albeit one that requires a high risk tolerance.
Source: fool.com